The coexistence of coronary artery disease(CAD)and atrial fibrillation(AF)is common in clinical practice.Patients with CAD require antiplatelet therapy to reduce the occurrence of myocardial ischemic events.However,pa...The coexistence of coronary artery disease(CAD)and atrial fibrillation(AF)is common in clinical practice.Patients with CAD require antiplatelet therapy to reduce the occurrence of myocardial ischemic events.However,patients with AF at high risk of thromboembolism require oral anticoagulants to reduce the occurrence of thromboembolic events such as stroke.In cases where CAD coexists with AF,the combined use of antiplatelet and anticoagulation therapy can effectively reduce the risk of ischemic and thromboembolic events but increase the risk of bleeding at the same time.The optimal antithrombotic regimen in patients with both CAD and AF has been controversial in clinical practice.In recent years,the expert consensuses on antithrombotic therapy in patients with AF presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention have been successively released in Europe and North America,and have been updated in a timely manner.In contrast,the guidelines on antithrombotic therapies in China are lacking.Based on published clinical evidence,this consensus incorporated relevant international and Chinese guidelines,consensuses,and expert recommendations,and addressed the issues encountered in the clinical practice of antithrombotic therapy in patients with AF and different types of CAD.The current guideline is of great significance to guide treatment in patients with both CAD and AF in China.展开更多
Cardiovascular disease is the leading cause of mortality in China.Primary prevention of cardiovascular disease with a focus on lifestyle intervention and risk factor control has been shown to effectively delay or prev...Cardiovascular disease is the leading cause of mortality in China.Primary prevention of cardiovascular disease with a focus on lifestyle intervention and risk factor control has been shown to effectively delay or prevent the occurrence of cardiovascular events.To promote a healthy lifestyle and enhance the detection,diagnosis,and treatment of cardiovascular risk factors such as hypertension,dyslipidemia,and diabetes,and to improve the overall capacity of primary prevention of cardiovascular disease,the Chinese Society of Cardiology of Chinese Medical Association has collaborated with multiple societies to summarize and evaluate the latest evidence with reference to relevant guidelines and subsequently to develop recommendations for primary cardiovascular disease prevention in Chinese adults.The guideline consists of 10 sections:introduction,methodology for developing the guideline,epidemiology of cardiovascular disease in China and challenges in primary prevention,general recommendations for primary prevention,assessment of cardiovascular risk,lifestyle intervention,blood pressure control,lipid management,management of type 2 diabetes,and use of aspirin.The promulgation and implementation of this guideline will play a key role in promoting the practice of primary prevention for cardiovascular disease in China.展开更多
基金supported by the National Key Research and Development Projects(No.2018YFC1312502)to Shulin Wu。
文摘The coexistence of coronary artery disease(CAD)and atrial fibrillation(AF)is common in clinical practice.Patients with CAD require antiplatelet therapy to reduce the occurrence of myocardial ischemic events.However,patients with AF at high risk of thromboembolism require oral anticoagulants to reduce the occurrence of thromboembolic events such as stroke.In cases where CAD coexists with AF,the combined use of antiplatelet and anticoagulation therapy can effectively reduce the risk of ischemic and thromboembolic events but increase the risk of bleeding at the same time.The optimal antithrombotic regimen in patients with both CAD and AF has been controversial in clinical practice.In recent years,the expert consensuses on antithrombotic therapy in patients with AF presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention have been successively released in Europe and North America,and have been updated in a timely manner.In contrast,the guidelines on antithrombotic therapies in China are lacking.Based on published clinical evidence,this consensus incorporated relevant international and Chinese guidelines,consensuses,and expert recommendations,and addressed the issues encountered in the clinical practice of antithrombotic therapy in patients with AF and different types of CAD.The current guideline is of great significance to guide treatment in patients with both CAD and AF in China.
文摘Cardiovascular disease is the leading cause of mortality in China.Primary prevention of cardiovascular disease with a focus on lifestyle intervention and risk factor control has been shown to effectively delay or prevent the occurrence of cardiovascular events.To promote a healthy lifestyle and enhance the detection,diagnosis,and treatment of cardiovascular risk factors such as hypertension,dyslipidemia,and diabetes,and to improve the overall capacity of primary prevention of cardiovascular disease,the Chinese Society of Cardiology of Chinese Medical Association has collaborated with multiple societies to summarize and evaluate the latest evidence with reference to relevant guidelines and subsequently to develop recommendations for primary cardiovascular disease prevention in Chinese adults.The guideline consists of 10 sections:introduction,methodology for developing the guideline,epidemiology of cardiovascular disease in China and challenges in primary prevention,general recommendations for primary prevention,assessment of cardiovascular risk,lifestyle intervention,blood pressure control,lipid management,management of type 2 diabetes,and use of aspirin.The promulgation and implementation of this guideline will play a key role in promoting the practice of primary prevention for cardiovascular disease in China.
